News

FDA has approved Actelion’s supplemental New Drug Application (sNDA) for Tracleer (bosentan) to treat patients with mildly symptomatic WHO Functional Class II (FC II) pulmonary arterial hypertension (PAH).

AlphaRx has received China patent for its topical platform technology – Vehicle For Topical Delivery of Anti-Inflammatory Compounds. The platform is an integral part of the company’s clinical

Cardiome and its co-development partner Astellas have reported that Astellas will undertake a single confirmatory additional phase 3 clinical trial of KYNAPID (vernakalant hydrochloride) Injection, for rapid conversion

FDA has approved Actelion’s new 20mcg/ml formulation of Ventavis as a therapy for New York Heart Association Class III and IV pulmonary arterial hypertension (PAH). The new increased

BioVectra has completed the manufacturing of DispersinB Topical Wound Gel under current Good Manufacturing Practices (cGMP). The required quality control (QC) tests, including sterility and DispersinB and alginate

Array BioPharma (Array) has reported positive top-line data from a phase 1 clinical trial of its novel small molecule glucokinase activator (GKA) – ARRY-403. The drug met its

Array BioPharma (Array) has reported revenue of $5.5m for the fourth quarter of fiscal 2009, compared to $6.1m for the same period in fiscal 2008. The company reported

Pharmasset has reported a net loss of $6.9m, or $0.25 per share, for the third quarter ended June 30, 2009, as compared to a net loss of $15.0m,

SCG-Dow Group, a joint venture between The Dow Chemical Company (Dow) and Siam Cement Group (SCG), has said that the construction of specialty elastomers plant in the Asia